Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing

Reuters

09/29

Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing

**Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571145381"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571145381\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571145381?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571145381","market":"fut","top_or_hot":-1,"title":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 18:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02576","symbol_name":"太美医疗科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDLc58x5c:1","article_id":"2571145381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571145381","pubTimestamp":1759141053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02576":"太美医疗科技","BK1141":"生命科学工具和服务"},"translate_title":"浙江太美医疗科技股份有限公司宣布向证监会提交H股全流通申请，启动转股及香港上市监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02576":0.9},"content_text":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    \n\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}